Gene profiling assay and application: The predictive role in primary therapy

Journal of the National Cancer Institute - Monographs

Volumn , Issue 43, 2011, Pages 124-127

  Fumagalli, Debora ^a   Desmedt, Christine ^a   Ignatiadis, Michail ^a   Loi, Sherene ^a   Piccart, Martine ^a   Sotiriou, Christos ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; AROMATASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; KI 67 ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; TAMOXIFEN; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RESISTANCE; CANCER STAGING; CLINICAL DECISION MAKING; DISCRIMINANT ANALYSIS; ENDOCRINE ASPECTS OF AGING; GENE EXPRESSION PROFILING; HUMAN; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; POSTMENOPAUSE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; BREAST TUMOR; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; METHODOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR MARKERS, BIOLOGICAL;

EID: 84855174024     PISSN: 10526773     EISSN: 17456614     Source Type: Book Series    
DOI: 10.1093/jncimonographs/lgr040     Document Type: Article

References (37)

1. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003, 362(9381): 362-369.
2. Hannemann J, Oosterkamp HM, Bosch CA, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol. 2005, 23(15): 3331-3342.
3. Hess KR, Anderson K, Symmans W, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol. 2006, 24(26): 4236-4244.
4. Thuerigen O, Schneeweiss A, Toedt G, et al. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J Clin Oncol. 2006, 24(12): 1839-1845.
5. Farmer P, Bonnefoi H, Anderle P, et al. A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med. 2009, 15(1): 68-74.
6. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med. 2009, 360(8): 790-800.
7. Tabchy A, Valero V, Vidaurre T, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clin Cancer Res. 2010, 16(21): 5351-5361.
8. Desmedt C, Di Leo A, Azambuja E, et al. Multi-factorial approach to predicting resistance to anthracyclines. J Clin Oncol. 2011, 29(12): 1578-1586.
9. Bild AH, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006, 439(7074): 353-357.
10. Miller WR, Larionov A, Renshaw L, et al. Gene expression profiles differentiating between breast cancer clinically responsive or resistant to letrozole. J Clin Oncol. 2009, 27(9): 1382-1387.
11. Mello-Grand M, Singh V, Ghimenti C, et al. Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically respectable breast cancer. Breast Cancer Res Treat. 2010, 121(2): 399-411.
12. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998, 16(8): 2672-2685.
13. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004, 351(27): 2817-2826.
14. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002, 415(6871): 530-536.
15. Sotiriou C, Wirapati P, Loi S, et al. Expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst. 2006, 98(4): 262-272.
16. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006, 24(23): 3726-3734.
17. Albain KS, Barlow WE, Shak S. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 2010, 11(1): 55-65.
18. Knauer M, Mook S, Rutgers EJ, et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat. 2010, 120(3): 655-661.
19. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005, 23(29): 7265-7277.
20. Straver ME, Glas AM, Hannemann J, et al. The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer. Breast Cancer Res Treat. 2010, 119(3): 551-558.
21. Liedtke C, Hatzis C, Symmans WF, et al. Genomic grade index is associated with response to chemotherapy in patients with breast cancer. J Clin Oncol. 2009, 27(19): 3185-3191.
22. Wirapati P, Sotiriou C, Kunkel S, et al. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res. 2008, 10(4): R65.
23. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res. 2008, 14(16): 5158-5165.
24. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005, 23(22): 5108-5116.
25. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001, 19(18): 3808-3816.
26. Sabine VS, Sims AH, Macaskill EJ. Gene expression profiling of response to mTOR inhibitor everolimus in pre-operatively treated post-menopausal women with oestrogen receptor-positive breast cancer. Breast Cancer Res Treat. 2010, 122(2): 419-428.
27. Potti A, Dressman HK, Bild A, et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med. 2006, 12(11): 1294-1300.
28. Coombes KR, Wang J, Baggerly KA. Microarrays: retracing steps. Nat Med. 2007, 13(11): 1276-1277.
29. Lee JK, Coutant C, Kim YC, et al. Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res. 2010, 16(2): 711-718.
30. Liedtke C, Wang J, Tordai A, et al. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Res Treat. 2010, 121(2): 301-309.
31. Michiels S, Koscielny S, Hill C, et al. Prediction of cancer outcome with microarrays: a multiple random validation strategy. Lancet. 2005, 365(9458): 488-492.
32. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000, 406(6797): 747-752.
33. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001, 98(19): 10869-10874.
34. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A. 2003, 100(18)10393-10398.
35. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005, 11(16): 5678-5685.
36. Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008, 26(8): 1275-1281.
37. Andre F, Mazouni C, Liedtke C, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. Breast Cancer Res Treat. 2008, 108(2): 183-190.